HiRO完成收購美國臨床研究組織Courante Oncology,持續拓展全球佈局和運營能力
廠商名稱:賀維斯特國際醫藥有限公司
發佈日期:2025-05-12
攤位號碼:M435
Aug. 31, 2023 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), an innovation global CRO, is pleased to announce the successful acquisition of Courante Oncology, a US-based full-service clinical research provider specializing in oncology product development.
As a reputable boutique CRO with a strong track record of delivering high-quality, expedited clinical trials in the Asia-Pacific, HiRO's acquisition of Courante Oncology marks a significant milestone in its global expansion. This strategic move further strengthens HiRO's capabilities in managing global studies, extending its presence into the US market.
Courante Oncology brings over 25 years of invaluable experience in the drug development industry. The company's expertise spans all aspects of phase 1-3 clinical trials, ranging from initial feasibility studies and protocol development to site monitoring and closeout visits. Renowned for their dedicated commitment to oncology research and clinical trial management, the Courante team has earned a remarkable reputation in the industry.
The synergy between HiRO and Courante Oncology creates a powerful partnership that will deliver successful clinical trials tailored to meet the evolving needs of the industry. Both companies possess robust clinical research networks, covering the Asia-Pacific region and the US, ensuring a seamless integration of expertise and resources.
"We are thrilled to welcome Courante Oncology into the HiRO family," said Dr. Karen Chu, Founder and CEO of HiRO. "This acquisition allows us to leverage Courante's extensive experience in oncology trials and enhance our capabilities in managing global studies. Together, we strive to deliver best-in-class cross-border solutions and relentless accountability that set us apart in the demanding clinical trial landscape. Our focus remains on accelerating the delivery of innovative medicines with simple, rapid, cost-effective clinical research solutions across the commercialization pathway."
"This marks an exciting chapter for Courante as we join forces with HiRO," said Sheri Smith, President of Courante Oncology. "We are excited to join the HiRO family and collaborate closely with their team. This integration will enable us to further expand our service offerings and functions into the US and beyond. We look forward to collaborating with our clients, to deliver effective, streamlined clinical trial solutions that meet and exceed their expectations."
The acquisition of Courante Oncology represents a significant step forward for HiRO as it continues to solidify its position as a global CRO. With a strengthened presence in the US and expanded capabilities, HiRO is well-positioned to deliver innovative and expedited clinical trial solutions to its clients worldwide.
About HiRO:
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integration capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
About Courante Oncology:
Courante Oncology is a full-service clinical research provider specializing in oncology product development. The company offers a wide range of clinical trial management and support services to the pharmaceutical and medical device industries, including project management, clinical site monitoring, quality assurance, and medical writing services.
Courante Oncology believes the challenges of oncology clinical trials require a research team that is uniquely experienced and trained. The strength of Courante Oncology lies in the team's collective experience and ability to adapt to clients' specific research needs. For more information on Courante Oncology, please visit www.couranteoncology.com.
Media Contact:
info@harvestiro.com
更多參展商新聞稿
- Uncountable歡迎BlueNalu成為新客戶,推動細胞培養海鮮的未來發展 UNCOUNTABLE INC. / 2025-06-20
- 創甡生技的使命與價值主張 創甡生物科技股份有限公司 / 2025-06-18
- 對抗乳癌抗藥性 清大研發標靶新藥有重大突破 國立清華大學王慧菁老師團隊 / 2025-06-18
- 研發治療阿茲海默症及神經退化性疾病之新藥 中央研究院神經賦活團隊 / 2025-06-18
- 創新微流體液態切片系統,為大腸直腸癌復發監控帶來新解方 賽爾奈微生醫股份有限公司 / 2025-06-18
- 突破基因檢測限制 新型免疫治療輔助平台對接2025國際趨勢 賽爾奈微生醫股份有限公司 / 2025-06-18
- 樂敦製藥推介無動物來源幹細胞培養基「R:STEM」,加速再生醫療研究與開發,百年製藥背景打造再生醫療 樂敦製藥株式會社 / 2025-06-16
- 隆重推出 5L DynaDrive 一次性生物反應器以簡化並加速製程開發,加快療法上市時程 台灣賽默飛世爾科技股份有限公司 / 2025-06-12
- 日本兩位細胞製造權威現身,聚焦《QbD實現的PAT》與《細胞製造中的QbD實踐與製程設計策略》 宏騏實業股份有限公司 / 2025-06-12
- 迎接減毒規範新時代!宏騏實業力推BioLife減毒hPL產品 助業界快速符合法規搶占市場 宏騏實業股份有限公司 / 2025-06-12
- NanoDrop Ultra - 重新定義微量樣本分析 博克科技股份有限公司 / 2025-06-12
- Microbs iAN® - 15分鐘快速無菌檢測 博克科技股份有限公司 / 2025-06-12
- IOT無線連續監測系統 - 廠房、倉儲、實驗室 溫、濕度測繪 幸託有限公司 / 2025-06-11
- 台灣基因治療之父胡務亮,攜手啟弘生技推動罕見疾病的基因治療 啟弘生物科技股份有限公司 / 2025-06-11
- 專業的動物實驗服務是您進行藥物測試的最佳助手 台灣小鼠診所與動物設施聯盟 / 2025-06-11
- 完整的動物實驗平台,解決你藥物測試及臨床前驗證的困擾 台灣小鼠診所與動物設施聯盟 / 2025-06-11
- 打造智慧細胞製程鏈:恆順生物整合樣本前處理、自動化培養與外泌體應用 恆順生物科技股份有限公司 / 2025-06-09
- 當代藥篩新選擇:恆順生物串聯3D培養與擬真微環境,打造體外模型新標竿。 恆順生物科技股份有限公司 / 2025-06-09
- 為何選擇Mecademic微型機器人做實驗室自動化? 今鈺科技有限公司 / 2025-06-07
- 怡定興生醫開創微針的未來 怡定興生醫股份有限公司 / 2025-06-06